Recent Updates — AMIX
Autonomix Medical, Inc. expanded its Board of Directors from five to six members by appointing Sandra Kalter as an independent director effective September 14, 2026. Ms. Kalter brings over four decades of medical device industry experience, most recently serving as Vice President and Chief Regulatory Counsel at Medtronic plc, where she oversaw regulatory strategy for global operations and managed due diligence for more than 27 acquisitions. Her background includes significant involvement with major platforms such as renal denervation and electrophysiology technologies. She will participate in the company's standard compensation program for non-employee directors but has not been assigned to any specific committees at this time. Autonomix Medical, Inc. operates in the medical device industry, developing catheter-based microchip sensing arrays for nerve-targeted treatments.
On August 24, 2026, Autonomix Medical entered into a warrant inducement agreement requiring the holder of existing Series D-1 and D-2 warrants to exercise them for 857,462 shares at $5.75 per share. The company anticipates receiving approximately $4.9 million in gross proceeds from this cash exercise. In consideration, Autonomix issued new unregistered Series E-1 and E-2 warrants to purchase a combined 1,071,826 shares at an exercise price of $6.25 per share. These new warrants are immediately exercisable with a five-year term and include beneficial ownership limitations and fundamental transaction protections. Maxim Group LLC served as the financial advisor for the transaction.
On July 13, 2026, Autonomix Medical, Inc. entered into a warrant inducement agreement with a holder of Series C warrants issued on November 19, 2025. The company reduced the exercise price of 428,731 existing warrants to $6.00 per share, expecting aggregate gross proceeds of approximately $2.6 million. In exchange, the company issued two new unregistered warrants (Series D-1 and Series D-2), each allowing the purchase of 428,731 shares at an exercise price of $5.75 per share with a 5.5-year term. Maxim Group LLC served as the solicitation agent and will receive a cash fee of 7.0% of the total proceeds plus expenses up to $15,000. Autonomix Medical is a medical device company that develops precision nerve-targeted treatments for diseases involving the nervous system.
Autonomix Medical, Inc. received a letter from Nasdaq notifying the company's common stock has regained compliance with the Bid Price Rule after the closing bid price remained at or above $1.00 per share for 10 consecutive business days from June 24, 2026, through July 8, 2026. Autonomix Medical, Inc. operates in the medical technology industry and develops diagnostic tools for gastrointestinal health.
Autonomix Medical, Inc. has announced a 1-for-21 reverse stock split of its common stock, effective June 24, 2026. The split will reduce the number of outstanding shares from 11,409,344 to approximately 542,000 shares. Autonomix Medical, Inc. operates in the medical technology industry and develops specialized medical devices for diagnostic and diagnostic-related services.